{"corpus_id":207670482,"paper_sha":"3fa2837ddaab6cc94202c8db688c65b81a3b1a46","doi":"10.1016/j.eururo.2018.08.027","arxiv_id":null,"pmid":30213523,"pmcid":null,"mag_id":2890512043,"dblp_id":null,"acl_id":null,"title":"Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.","year":2019,"publication_date":"2019-03-01","venue":"European Urology","journal":{"name":"European urology","pages":"\n          423-432\n        ","volume":"75 3"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Meta-Analysis","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Biology","Medicine"],"reference_count":46,"citation_count":235,"influential_citation_count":9,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Aged, 80 and over","mj":false,"ui":"D000369"},{"d":"Biomarkers, Tumor","mj":false,"qs":[{"q":"genetics","mj":true,"ui":"Q000235"}],"ui":"D014408"},{"d":"Carcinoma","mj":false,"qs":[{"q":"classification","mj":false,"ui":"Q000145"},{"q":"genetics","mj":true,"ui":"Q000235"},{"q":"mortality","mj":false,"ui":"Q000401"},{"q":"pathology","mj":false,"ui":"Q000473"}],"ui":"D002277"},{"d":"Databases, Genetic","mj":false,"ui":"D030541"},{"d":"Disease Progression","mj":false,"ui":"D018450"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Gene Expression Profiling","mj":false,"ui":"D020869"},{"d":"Gene Expression Regulation, Neoplastic","mj":false,"ui":"D015972"},{"d":"Genetic Predisposition to Disease","mj":false,"ui":"D020022"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Phenotype","mj":false,"ui":"D010641"},{"d":"Prognosis","mj":false,"ui":"D011379"},{"d":"Risk Assessment","mj":false,"ui":"D018570"},{"d":"Risk Factors","mj":false,"ui":"D012307"},{"d":"Transcriptome","mj":true,"ui":"D059467"},{"d":"Urinary Bladder Neoplasms","mj":false,"qs":[{"q":"classification","mj":false,"ui":"Q000145"},{"q":"genetics","mj":true,"ui":"Q000235"},{"q":"mortality","mj":false,"ui":"Q000401"},{"q":"pathology","mj":false,"ui":"Q000473"}],"ui":"D001749"},{"d":"Urothelium","mj":false,"qs":[{"q":"chemistry","mj":true,"ui":"Q000737"},{"q":"pathology","mj":false,"ui":"Q000473"}],"ui":"D019459"},{"d":"Young Adult","mj":false,"ui":"D055815"}],"chemicals":[{"n":"Biomarkers, Tumor","ui":"D014408","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BACKGROUND\nPrevious molecular subtyping for bladder carcinoma (BLCA) involved <450 samples, with diverse classifications.\n\n\nOBJECTIVE\nTo identify molecular subtypes by curating a large BLCA dataset.\n\n\nDESIGN, SETTING, AND PARTICIPANTS\nGene expression publicly available were combined and reanalyzed. The dataset contained 2411 unique tumors encompassing non-muscle-invasive (NMIBC) and muscle-invasive BLCA (MIBC). Subtypes were reproduced on The Cancer Genome Atlas, UROMOL, and IMvigor210.\n\n\nINTERVENTION\nSubtypes were assigned by gene expression.\n\n\nOUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS\nKaplan-Meier analyses were performed for subtype-clinical outcome correlations; Chi-square/Fisher exact tests were used for subtype-clinicopathological parameters associations.\n\n\nRESULTS AND LIMITATIONS\nWe identified six molecular subtypes with different overall survival (OS) and molecular features. Subtype Neural-like (median OS, 87 mo) is prevalent in MIBC and characterized by high WNT/β-catenin signaling. HER2-like (107.7 mo) is distributed evenly across NMIBC and MIBC, with higher ERBB2 amplification and signaling. Papillary-like (>135 mo), an NMIBC subtype enriched in urothelial differentiation genes, shows a high frequency of actionable FGFR3 mutations, amplifications, and FGFR3-TACC3 fusion. Luminal-like (91.7 mo), predominantly NMIBC, has higher MAPK signaling and more KRAS and KMT2C/D mutations than other subtypes. Mesenchymal-like (MES; 86.6 mo) and Squamous-cell carcinoma-like (SCC; 20.6 mo) are predominant in MIBC. MES is high in AXL signaling, whereas SCC has elevated PD1, CTLA4 signaling, and macrophage M2 infiltration. About 20% of NMIBCs show MIBC subtype traits and a lower 5-yr OS rate than Papillary-like NMIBC (81% vs 96%). The main limitations of our study are the incomplete clinical annotation, and the analyses were based on transcriptome subset due to comparisons across gene expression quantification technologies.\n\n\nCONCLUSIONS\nBLCA can be stratified into six molecular subtypes. NMIBC, with a high risk of progression, displays the molecular features of MIBC.\n\n\nPATIENT SUMMARY\nBiomarkers are urgently needed to guide patient treatment selection and avoid unnecessary toxicities in those who fail to respond. We believe molecular subtyping is a promising way to tailor disease management for those who will benefit most.","claims":[{"public_id":"cl_33761ab3dd5989f5936190b33e943b9e","status":"active","text":"About 20% of non-muscle-invasive bladder cancers show muscle-invasive subtype traits and have a lower 5-year overall survival rate than Papillary-like non-muscle-invasive tumors.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_33761ab3dd5989f5936190b33e943b9e"},{"public_id":"cl_03b84d3a7849626e219d9c532abea281","status":"active","text":"Bladder cancer can be stratified into six molecular subtypes with distinct overall survival and molecular features.","confidence":0.99,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_03b84d3a7849626e219d9c532abea281"},{"public_id":"cl_ead813d7f72adf3042f67b3235ea4025","status":"active","text":"HER2-like subtype is evenly distributed across non-muscle-invasive and muscle-invasive bladder cancer and shows higher ERBB2 amplification and signaling.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_ead813d7f72adf3042f67b3235ea4025"},{"public_id":"cl_ac24a6f542333ff4ec356fd8922242d9","status":"active","text":"Neural-like subtype is prevalent in muscle-invasive bladder cancer and is characterized by high WNT/β-catenin signaling.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_ac24a6f542333ff4ec356fd8922242d9"},{"public_id":"cl_fea2d403f750e3606a718c6f39632c6c","status":"active","text":"Papillary-like subtype is enriched in non-muscle-invasive bladder cancer and shows a high frequency of actionable FGFR3 mutations, amplifications, and FGFR3-TACC3 fusion.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_fea2d403f750e3606a718c6f39632c6c"}],"concepts":[{"public_id":"co_022738428896bc56088205ff5f1e6d15","status":"active","name":"Papillary-like subtype","description":"A bladder cancer molecular subtype enriched for papillary and urothelial differentiation features.","types":["molecular subtype"],"aliases":["Papillary-like"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_022738428896bc56088205ff5f1e6d15"},{"public_id":"co_0d19751000894794ae5c35b3f1e2f37c","status":"active","name":"molecular subtypes","description":"Distinct transcriptomic groupings used to classify bladder cancer tumors by gene-expression patterns.","types":["classification scheme"],"aliases":["subtypes"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0d19751000894794ae5c35b3f1e2f37c"},{"public_id":"co_17241f8ff1a0556b22393a467127151a","status":"active","name":"Neural-like subtype","description":"A bladder cancer molecular subtype associated with neural-like expression features and WNT/β-catenin signaling.","types":["molecular subtype"],"aliases":["Neural-like"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_17241f8ff1a0556b22393a467127151a"},{"public_id":"co_19018a25cf075891cd432230e6db8a3b","status":"active","name":"5-year overall survival","description":"The proportion of patients alive five years after a reference time point.","types":["outcome measure"],"aliases":["5-yr OS"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_19018a25cf075891cd432230e6db8a3b"},{"public_id":"co_1b90cf82a8f7425496212787ee069baf","status":"active","name":"FGFR3-TACC3 fusion","description":"A gene fusion between FGFR3 and TACC3 found as a tumor alteration.","types":["gene fusion"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1b90cf82a8f7425496212787ee069baf"},{"public_id":"co_4ef755eeb96cd68475f6dd92afe0812e","status":"active","name":"WNT/β-catenin signaling","description":"A signaling pathway involving WNT ligands and β-catenin, assessed as a molecular feature of tumors.","types":["signaling pathway"],"aliases":["WNT/beta-catenin signaling"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4ef755eeb96cd68475f6dd92afe0812e"},{"public_id":"co_6a2a8a13e6e18698b0e1882d7d5a75da","status":"active","name":"muscle-invasive bladder cancer","description":"Bladder cancer that has invaded the detrusor muscle layer.","types":["cancer stage"],"aliases":["MIBC"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6a2a8a13e6e18698b0e1882d7d5a75da"},{"public_id":"co_7022580e8cdeb7de2e28f29094a2445a","status":"active","name":"bladder cancer","description":"A malignant tumor of the urinary bladder analyzed in the meta-cohort.","types":["cancer type"],"aliases":["BLCA","urothelial bladder cancer"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7022580e8cdeb7de2e28f29094a2445a"},{"public_id":"co_70c8b40c535753c023efd5ae49957a7f","status":"active","name":"overall survival","description":"Time from diagnosis or treatment to death from any cause, used as a clinical outcome measure.","types":["outcome measure"],"aliases":["OS"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_70c8b40c535753c023efd5ae49957a7f"},{"public_id":"co_7116d51475c07b3ab14e598409d06fac","status":"active","name":"HER2-like subtype","description":"A bladder cancer molecular subtype associated with ERBB2-related expression and amplification features.","types":["molecular subtype"],"aliases":["HER2-like"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7116d51475c07b3ab14e598409d06fac"},{"public_id":"co_858e5002eef53010b4c425598a73e4d6","status":"active","name":"ERBB2 amplification","description":"Copy-number increase of the ERBB2 gene, a genomic alteration measured in the tumors.","types":["genomic alteration"],"aliases":["HER2 amplification"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_858e5002eef53010b4c425598a73e4d6"},{"public_id":"co_8f552e5f82702c339996459a2aceaff5","status":"active","name":"non-muscle-invasive bladder cancer","description":"Bladder cancer confined to the mucosa or submucosa without muscle invasion.","types":["cancer stage"],"aliases":["NMIBC"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8f552e5f82702c339996459a2aceaff5"}],"external_ids":{"DOI":"10.1016/j.eururo.2018.08.027","ArXiv":null,"PubMed":30213523,"PubMedCentral":null,"MAG":2890512043,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/207670482","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631773,"paper_uid":"297de065-4462-4526-8f09-5ce265d01092","canonical_identity":{"paper_id":631773,"paper_uid":"297de065-4462-4526-8f09-5ce265d01092","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/207670482"}